T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy in which the transformed clone is arrested during T-cell development. Despite significant improvements in treatment outcome, survivors tend to face long term complications and develop serious secondary health problems. Therefore, the current challenge is to develop more efficient therapeutic strategies that target the leukemia cells in a more specific way, diminishing the toxic effects of the treatment.
